Search

Showing 71 - 80 of 525 results.

Patients who benefit

49% of patients with symptomatic severe MR were not operated due to age, co-morbidities, or impaired LV.5 If left untreated, MR initiates a cascade of events leading to death, with 1-year…
TAVI Summit 2025

ON DEMAND - TAVI SUMMIT 2025 3rd Abbott Annual Transcatheter Aortic Valve Implantation Summit SESSION 1: BEYOND THE TAVI IMPLANT: A STRATEGIC APPROACH TO LIFETIME MANAGEMENT SESSION 2:…
LAAO Summit 2025

ON DEMAND - LAAO SUMMIT 2025 14th International Left Atrial Appendage Occlusion Summit SESSION 1: PATIENT SELECTION & PRE-PROCEDURAL PLANNING SESSION 2: PROCEDURAL OPTIMIZATION & IMAGING…
Overview

LEARN MORE: AMPLATZER™ TALISMAN™ PFO OCCLUDER Clinical data Diagnosis Prevention PFO CLOSURE: BEHIND THE NUMBERS Ischemic strokes are of unknown cause5 Of patients with an…
Clinical Data

NYHA: New York Heart Association LEARN MORE: CLINICAL Trials Clinical Case Compendium A SOLUTION THAT HAS RECEIVED CLOSE ATTENTION5–7, 10,11 — AND STRONGLY POSITIVE REVIEWS.12 …
Clinical Data

SWITCH TO THE interventional VIEW For more information specific to interventional cardiology regarding PDA closure CAP=continued access protocol, IDE=investigational device…
Overview

SWITCH TO THE interventional VIEW For more information specific to interventional cardiology regarding PDA closure If PDA is left untreated, the mortality rate is 20% by age 20…
Diagnosis

PATENT DUCTUS ARTERIOSUS LEARN MORE: PATIENTS WHO BENEFIT
Overview

LEARN MORE: AMPLATZER™ DUCT OCCLUDERS AMPLATZER™ PICCOLO™ OCCLUDER WATCH ON-DEMAND: PDA Symposium 2024 If PDA is left untreated, the mortality rate is 20% by age 20…
Prevention

AF AND THE CHALLENGES OF MEDICATION Many patients at risk of stroke want an alternative to oral anticoagulants (OACs), for example, warfarin and non-vitamin K oral anticoagulants (NOACs).7 40% Do…